Shares of Myovant Sciences Ltd. were down 5.7% in premarket trading on Wednesday after the company told investors that the Food and Drug Administration had placed a partial clinical hold on a study assessing an experimental birth control. The drug, called a relugolix combination tablet, is also being tested as a treatment for uterine fibroids and endometriosis. Myovant said in a securities filing that the FDA put a partial hold on the Phase 3 study until the company adds monitoring for bone mineral density. Myovant’s stock is down 18.18% for the year, while the broader S&P 500 is up 9.9%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
